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Abstract
Background: The eMERGE (electronic MEdical Records and Genomics) network, funded by the National Human
Genome Research Institute, is a national consortium formed to develop, disseminate, and apply approaches to
research that combine DNA biorepositories with electronic health record (EHR) systems for large-scale, high-
throughput genetic research. Marshfield Clinic is one of five sites in the eMERGE network and primarily studied: 1)
age-related cataract and 2) HDL-cholesterol levels. The purpose of this paper is to describe the approach to
electronic evaluation of the epidemiology of cataract using the EHR for a large biobank and to assess previously
identified epidemiologic risk factors in cases identified by electronic algorithms.
Methods: Electronic algorithms were used to select individuals with cataracts in the Personalized Medicine
Research Project database. These were analyzed for cataract prevalence, age at cataract, and previously identified
risk factors.
Results: Cataract diagnoses and surgeries, though not type of cataract, were successfully identified using electronic
algorithms. Age specific prevalence of both cataract (22% compared to 17.2%) and cataract surgery (11%
compared to 5.1%) were higher when compared to the Eye Diseases Prevalence Research Group. The risk factors of
age, gender, diabetes, and steroid use were confirmed.
Conclusions: Using electronic health records can be a viable and efficient tool to identify cataracts for research.
However, using retrospective data from this source can be confounded by historical limits on data availability,
differences in the utilization of healthcare, and changes in exposures over time.
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Background
When considering diseases that impact public health
worldwide, few would outrank cataracts. Cataracts are
the leading cause of blindness worldwide [1]. Global
Burden of Disease 2004 from the World Health Organi-
zation ranks cataracts as fourth in disabling conditions
in the world following hearing loss, refractive errors,
and depression. It estimates the prevalence of moderate
and severe disability due to cataracts to be 53.8 million
for all ages worldwide [2].
While cataracts may be congenital or result from a
specific trauma, most cataracts are related to aging. As
the age demographic shifts upward in the population,
the incidence of age-related cataract will also increase.
In the United States it is estimated that 17.2% of those
age 40 and older have cataracts, and this rate is pro-
jected to increase by 50% by the year 2020 [3]. The pre-
valence of cataract surgery among Americans aged 40-
years and older is estimated at 5.1%, and that is likely to
increase by almost 60% by the year 2020 [3]. There is
also the suggestion that with the predicted ozone deple-
tion, the rate of cortical cataracts will increase above the
expected levels, resulting in an even higher prevalence
of cataracts by the year 2050 [4]. Learning to prevent or
delay cataract formation will be an essential part of
addressing the growing public health problem of
cataracts.
A necessary part of learning to prevent or delay the
formation of cataracts is to understand what contributes
to their formation. Environmental factors previously
reported as being associated with increased rates of cat-
aract include: chronic steroid use, smoking, sun
* Correspondence: waudby.carol@mcrf.mfldclin.edu
1Center for Human Genetics, Marshfield Clinic Research Foundation,
Marshfield, Wisconsin, USA
Full list of author information is available at the end of the article
Waudby et al. BMC Ophthalmology 2011, 11:32
http://www.biomedcentral.com/1471-2415/11/32
© 2011 Waudby et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.exposure, diabetes, and elevated body mass index (BMI)
[5]. Possible protective factors reported include higher
intake of antioxidants, increased physical activity, and
certain medications [6].
The electronic MEdical Records and GEnomics
(eMERGE) network was formed to develop, disseminate,
and apply methods for performing complex genomic
analysis utilizing electronic health record (EHR) systems
as a resource to determine diseases and therapeutic out-
comes. A primary goal of eMERGE is to develop and
validate electronic algorithms that accurately and effec-
tively classify patients with respect to specific medical
conditions such as cataracts [7]. Ultimately, validated
phenotypes will be applied across medical records at
many facilities in order to improve the efficiency of
medical research [8].
The purpose of this study was to develop, validate,
and use electronic algorithms to identify cases of age-
related cataracts in a population-based biobank and to
evaluate the prevalence of cataracts and previously
established clinical risk factors for developing cataracts
using those algorithms.
Methods
This study was designed as a retrospective review of a
well-established cohort utilizing data from a comprehen-
sive EHR. All individuals in the cohort provided written
informed consent, and the project was reviewed and
approved by the Marshfield Clinic’s Institutional Review
Board.
Study Population
This study population was comprised of participants
within the Personalized Medicine Research Project
(PMRP). The PMRP is a geographically defined, popula-
tion-based biobank with over 20,000 subjects, age 18-
years and above, enrolled from the Marshfield Clinic
healthcare system in Central Wisconsin [9]. The bio-
bank includes DNA, plasma, and serum samples col-
lected at the time of consent. The written informed
consent document allows ongoing access to medical
records, thereby enabling a wide range of medical
research. Participants complete questionnaires that
include information on smoking history, occupation,
and diet.
Data Collection
Initially, Current Procedural Terminology (CPT) codes
in the Marshfield Clinic EHR were used to select indivi-
duals who had cataract surgery and were age 50+ years
at the time of their earliest cataract surgical procedure.
Congenital and traumatic type cataracts were excluded.
There were 2881 total surgeries indicated electronically
among 1740 unique individuals. The charts were all
manually abstracted by a research coordinator for eye,
type of cataract, severity of cataract, and visual acuity
just prior to surgery. They were also verified to rule out
congenital or traumatic type cataracts. This resulted in
2811 valid surgeries and 1703 unique individuals. Infor-
mation from this manual abstraction was used to
improve the positive predictive value of the electronic
algorithm.
To identify individuals having cataract diagnosis with-
out surgery, International Classification of Diseases, 9th
revision (ICD-9) and CPT codes were used. In addition,
Natural Language Processing (NLP) and Intelligent
Character Recognition (ICR) were used to help deter-
mine a cataract diagnosis and to identify type of catar-
act. Using NLP, text-based documents in the EHR were
searched for the mention of cataract and cataract types
in order to determine a cataract diagnosis. Handwritten
documents stored electronically in the EHR were
searched for cataract type and severity using ICR [10].
Excluding congenital and traumatic cataract diagnoses,
3035 individuals were identified with a cataract diagno-
sis and no surgery on or before the data cut off date of
1-15-2008. Of those identified, 1717 (56.6%) were veri-
fied by manual abstraction identifying eye, cataract type,
severity, visual acuity, and were verified as not being
congenital or traumatic type cataract. This was done to
determine the positive predictive value of the selection
using codes, NLP, and ICR. Using a cataract definition
requiring at least one cataract surgical procedure code
with age 50+ years at earliest surgical procedure, or two
or more inclusion type diagnosis codes with age 50+
years at earliest inclusion type diagnosis code, or one
inclusion type diagnosis code with age 50+ years at ear-
liest inclusion type diagnosis and one or more NLP/ICR
hits, a weighted positive predictive value of 95.6% was
reached.
Smoking history was queried at enrollment into PMRP
with respect to whether participants had ever smoked at
least 100 cigarettes, as well as their current smoking sta-
tus. Many subjects (27%) had stopped smoking by the
time of enrollment in PMRP. The study’s primary com-
parison of smoking as a risk factor compared current
smokers at the time of enrollment to those who had
never smoked at the time of enrollment.
Dietary intake data were gathered retrospectively using
the National Cancer Institute’s Dietary History Ques-
tionnaire (DHQ) [11] sent to participants after the time
of enrollment [12]. The DHQ is comprised of 124 sepa-
rate food items and asks about portion sizes for most
foods. In addition, there are ten questions about nutri-
ent supplement intake. Software from the National Insti-
tutes of Health was used for the nutrient analyses of the
DHQ data [13]. Analyses for this study focused on the
combined intake of antioxidants (vitamins A, E, and C,
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including intake from supplements. Intake was observed
to be highly variable for the individual antioxidants. In
order to obtain a single antioxidant score, the individual
intakes were first converted to normal scores [14,15]
based on the ranking across PMRP subjects, and a mean
of the scores for all antioxidants was calculated for each
subject.
Baseline high-density lipoprotein (HDL) cholesterol
levels were estimated from laboratory results in the
EHR. Details of how baseline HDL was determined can
be found elsewhere [16], but in brief, this was accom-
plished by subsetting HDL values to outpatient results
prior to use of statins, fibrates, niacin, hormone replace-
ment therapy, and prior to any diagnosis of cancer, dia-
betes, or hypothyroidism. Further adjustments were
made based on the observed population trends in age
and BMI.
After screening procedures to eliminate gross errors in
height and weight measurements, BMI was estimated
from the EHR. The BMI results prior to cataract were
preferentially selected when available. Median BMI was
calculated for each subject and used in analyses.
Statin use was determined by selecting the earliest
date that statin use was mentioned in the EHR. To
determine whether steroid medications had been used,
diagnoses where treatment was expected to include the
use of steroid medications were identified from the
EHR. These diagnoses were categorized as to whether
suspicion of adrenal steroid use was > 50% or ≤ 50%.
For diagnoses where suspicion of adrenal steroid use
was > 50%, two or more unique diagnosis dates were
required. For diagnoses where suspicion of adrenal ster-
oid use was ≤ 50%, two or more unique diagnosis dates
and two or more unique adrenal steroid medication
mention dates were required.
Statistical analysis
Two primary outcome measures were analyzed: 1) the
current prevalence of cataract by age; and 2) age at first
clinical evidence of cataract. Although nearly all subjects
have two eyes in which cataracts may develop, it was
assumed that many factors affecting both exposures and
diagnosis sensitivity could change after a subject’sf i r s t
cataract event, and therefore, the analysis of subsequent
cataract events would require a separate evaluation that
will not be considered here. Even studies with prospec-
tive follow-up often limit analysis to the worst eye,
which would generally be the first eye diagnosed and/or
operated on, as used in these analyses.
In processing prior to cataract assessment, EHR data
for subjects showing any cataract exclusion codes (e.g.,
traumatic cataract) were right-censored, and this censor-
ing was applied one year prior to the date of their first
exclusion code to allow for delayed documentation of
the excluding event. Subjects who did not meet the cat-
aract case event definition provided varying periods of
observation time. In time-to-event analyses of age at
first cataract, such subjects were considered to be at-risk
for developing cataract up to their earliest age at either
of the following: a) the end of their “observation time”
in the EHR; or b) the occurrence of a censoring event.
Subjects have medical visits with varying frequency, and
it is possible that subjects not seen regularly in the
Marshfield Clinic system may have had a cataract that is
undocumented in the EHR. For this reason, and based
on review of observed visit histories, the final “observa-
tion time” for subjects without cataract was defined as
the date of the last diagnosis in a year where some diag-
noses were also recorded in one or more of the previous
four years. Censoring events included cataract exclusion
codes and valid cataract codes (including NLP indica-
tions) for subjects with such codes who did not meet
the event definition.
The simple prevalence of age-related cataract at
enrollment in PMRP was summarized by age group
with 95% confidence limits. In analyses of potential risk
factors, cataract prevalence was defined at the EHR data
acquisition (end of December 2007). These analyses
used logistic regression models, stratified by gender and
adjusted for age (with age covariates based on restricted
cubic splines) [15]. Results are summarized with esti-
mates of odds ratios, together with p-values and confi-
dence limits from asymptotic Wald tests. Results for
continuous factors (BMI, HDL, and antioxidant intake)
are presented for subjects divided into three equal sized
groups (lowest, middle, highest). Relative risks were
a s s u m e dt oc h a n g et os o m ed e g r e ew i t ha g e ,s om o d e l s
included interactions with age, and estimates are pro-
vided for ages 40 and 70. Graphical smoothing with
cubic splines was used to illustrate age trends in
prevalence.
Basic analyses of age at first cataract included Kaplan-
Meier estimates, and both log-rank and Wilcoxon tests
for differences are reported. The Wilcoxon test is
weighted by the number of subjects at risk and is there-
fore more sensitive to differences at younger ages relative
to the log-rank test. Risk factors for age at first cataract
were analyzed with proportional hazards regression mod-
els, with stratification by birth cohort and with gender as
a covariate. Results are summarized with estimates of
hazards ratios, together with p-values and confidence
limits from asymptotic Wald tests. Hazard ratios were
a s s u m e dt od i f f e rt os o m ed e g r e eb yb i r t hc o h o r t ,s o
models included interactions with birth cohort, and esti-
mates are provided for the youngest (born 1960 and
later) and oldest (born prior to 1940) cohorts. Results are
deemed statistically significant at the 5% level (p < 0.05).
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The PMRP analysis cohort included 19,622 subjects, ages
18 to 98 years (median 46.7 years) at enrollment. Fifty-
seven percent (11,222/19,622) were female and 97% were
white, non-Hispanic by self-report. The observed preva-
lence of age-related cataract by age at enrollment in PMRP
is shown by gender in Figure 1, together with prevalence
estimates for the white U.S. population in year 2000 from
the Eye Diseases Prevalence Research Group (EDPRG) [3].
Similarly, the observed prevalence of cataract surgery by
age at enrollment in PMRP is shown by gender in Figure 2,
together with the EDPRG estimates for pseudophakia/
aphakia. The prevalence of age-related cataract below age
30 was extremely low (< 0.2%), and all subsequent analyses
were limited to 16,336 PMRP subjects ages 30 and above
at the time of data collection (12/31/2007). Table 1 sum-
m a r i z e st h ec h a r a c t e r i s t i c so ft h i sa n a l y s i sc o h o r t .
As shown in Figure 3, there were clear differences in
age at first cataract by gender (p < 0.0001), with a differ-
ence of 2 years in the median age (median 71.7 years in
females; 73.7 years in males). There were also differ-
ences among those with and without clinical indications
of diabetes, but the differences were much stronger in
males (both log-rank and Wilcoxon p < 0.0001) than in
females (log-rank p = 0.004, Wilcoxon p = 0.498). This
is also reflected in Figure 4. To avoid confounding, sub-
sequent analyses of risk factors for cataract were strati-
fied by gender. In addition, clinical guidelines at
Marshfield Clinic recommend annual dilated eye exams
for patients with diabetes. Since less than 16% of the
cohort show clinical indications for diabetes, analyses of
other potential risk factors were restricted to those with
no indication of diabetes.
Rates of exposure to potential risk factors for cataract,
including such things as diet, exercise, smoking, medica-
tions, and exposure to sunlight, have changed substan-
tially over the last century [17-22]. Given the wide age
range in PMRP, it was important to consider when sub-
jects were born when evaluating associations of risk fac-
tors with the age-specific incidence of cataract in order
to avoid confounding among factors where the rate of
exposure had changed over time. Compounding the
need to adjust for birth year, although many clinical
diagnoses are available as early as 1960 in the Marsh-
field Clinic electronic health record, cataract and other
diagnoses from the ophthalmology department became
available only much later, in the period from 1992 to
1994. Figure 5 shows cataract incidence by birth cohort
in females without diabetes and shows a strong trend
for earlier incidence in subjects born more recently.
While some of this trend may be due to changing expo-
sures, the greatest factor is likely the historical trunca-
tion of the EHR. At this point in time, there is little
ability to detect, for example, diagnoses prior to age 50
in patients born before 1950. Largely for this reason,
potential risk factors for cataract were analyzed in two
different ways: 1) age at first cataract was analyzed with
proportional hazards models stratified by birth cohort;
and 2) 2007 prevalence of cataract was analyzed with
logistic regression models. The first approach (age at
first cataract) provides efficient analyses but may be par-
ticularly sensitive to historical limits on data availability.
The second approach (prevalence) will be more robust
to these data limitations but is not fully efficient in the
use of the data (e.g., a subject age 70 having a cataract
for 1 year appears the same as another subject age 70
having a cataract for 10 years).
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Figure 1 Prevalence of Cataract by Gender in PMRP and the
EDPRG.
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Page 4 of 15Table 2 summarizes the results of the analyses of age
at first cataract for the risk factors of interest. Model
results for gender alone are included, as are results for
diabetes stratified by gender. Models for the other fac-
tors of interest were fit in only those patients without
diabetes and were stratified by both gender and birth
cohort. The significance of each potential risk factor
(Main Effect) is shown as well as a test for differences
by birth cohort (Interaction).
Table 3 summarizes the results of the analyses of 2007
prevalence for the risk factors of interest. Model results for
gender alone are included, as are results for diabetes strati-
fied by gender. Models for the other potential risk factors
were fit in only those patients without diabetes, and were
stratified by gender and adjusted for age. The significance
of each potential risk factor (Main Effect) is shown as well
as a test for changes in the odds ratio by age (Interaction).
Evidence of the impact of smoking on cataract devel-
opment was most clear in the oldest cohort. Figure 6
displays the differences in the age cohorts. The estimate
of age at cataract is earlier for the oldest smokers with a
less clear distinction for each of the younger cohorts,
resulting in the suggestion of a protective factor with
decreased age. Figure 7 also shows the interaction of
smoking and age.
Table 1 Descriptive characteristics of the cataract
analysis cohort
Males Females Overall
Subjects (n %) 7,031
43%
9,305
57%
16,336
Cataracts (n %) 1437 20% 2167 23% 3604
22%
Median age of onset (yr) 67.1 65.6 66.2
Minimum 19 13 13
Maximum 90 90 90
Type
1 (%)
Nuclear 96.8% 97.1% 97.0%
Cortical 65.6% 72.1% 69.5%
Posterior subcapsular cataract
(PSC)
33.5% 35.9% 34.9%
Cataract surgery (n %) 681 10% 1118 12% 1799
11%
Median age (yr) 56.0 54.9 55.4
Minimum 30 30 30
Maximum 99 98 99
Diabetes (n %) 1243 18% 1305 14% 2548
16%
Smoking history (n %)
Never 3061 44% 5518 59% 8579
53%
Current 1255 18% 1427 15% 2682
16%
Other or unknown 2715 39% 2360 25% 5075
31%
Steroid use (n %) 1099 16% 1545 17% 2644
16%
Statin use (n %) 2718 39% 2684 29% 5402
33%
Median BMI (kg/m
2) 28.8 28.0 28.4
Minimum 17.6 15.1 15.1
Maximum 60.1 74.9 74.9
Median adjusted HDL (mg/dL)
2 46.1 58.4 52.6
Minimum 19.8 22.7 19.8
Maximum 112.0 118.3 118.3
Deceased (n %) 456 6% 376 4% 832 5%
1Cataract type available for 2719 subjects with cataract (1610 female, 1109
male.) Subjects may exhibit multiple types.
2 High density lipoprotein (HDL) results were limited to those prior to
treatment with statins and prior to diagnosis with a condition known to affect
HDL (e.g. thyroid disorders), and were subsequently adjusted for age and
body size (body mass index =BMI). At least 2 results were required, and these
were available for 7733 subjects (47%).
%
 
W
i
t
h
 
C
a
t
a
r
a
c
t
0
10
20
30
40
50
60
70
80
90
100
Age (years)
30 40 50 60 70 80
0
10
20
30
40
50
60
70
80
90
100
Female
Male
Dashed Lines = Subjects with Diabetes
_____  Females 
_____  Males   
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Page 5 of 15The use of steroids gave a more consistent picture.
Using steroids increases the risk of developing cataract.
Shown in Figures 8 and 9, cataracts tend to develop ear-
lier for all ages when steroids have been used. This
result was apparent even without adjustment for dosage
or duration of use for a steroid, only a presence or
absence of selected drugs.
The analyses on use of statins are shown in Figures 10
and 11 and indicate a possible increase in risk for catar-
act development. The survival analyses (Figure 10) show
significant main effects (p < 0.001) for both females and
males. The hazard ratio for the earliest birth cohort was
1.27 for females and 1.24 for males using statins.
While not significant, the analyses (Figures 12 and 13)
are in the direction of a protective effect with increased
BMI. In the prevalence analyses, (Table 3), the odds
ratio for the oldest cohort was .67 for females and .74
for males.
Consistent with the Framingham Study [23], no clear
association was found between HDL and cataract.
Results shown in Figures 14 and 15 comparing those
with the highest and the lowest HDL vary substantially
with increasing age. Similarly, no clear findings were
found for antioxidants. Shown in Figures 16 and 17, the
results vary substantially with age, and do not reach sta-
tistical significance.
Discussion
The estimates for cataract prevalence were notably
higher in PMRP above age 65 compared with the
EDPRG, but this may be due in part to the sensitivity of
the electronic criteria in PMRP to pick up low severity
cataract. However, the prevalence of surgery in PMRP is
also considerably higher above age 65, suggesting popu-
lation differences that might include more extensive
healthcare utilization in the population- based PMRP
cohort.
Being female and having diabetes were clearly asso-
ciated with cataract development. This has been shown
in other studies as well [24-26]. Because of this, analyses
of other risk factors in the current study were limited to
those without diabetes and were stratified by gender.
Some studies indicate a connection between smoking
and cataract development [24-26]. Analyses in the cur-
rent study were less clear. The suggestion of a possible
protective effect at earlier ages could well be a limitation
of the data, since younger subjects generally have less
need for regular health care visits and may not be get-
ting standard eye exams to have cataract diagnosed, or
this may be due to the lack of information related to
number of pack years.
As with other studies [27-29], the use of steroids was
also predictive of cataract development. Odds ratios in
the current study ranged from 1.31 to 2.44 for males
and females across all ages, while those found by Curtis
[29] ranged from 1.19 to 1.83 for cumulative dose.
Risk factors (age, female, diabetes, and steroids) that
have been found to be robust or conclusive were also
identified in the current study. It should be noted that
the risk factors (statins, BMI, HDL, antioxidants) where
results in the current study differed from other studies
or were not found, have been ones that have previously
had limited or conflicting results. For statins, the current
s t u d ys h o w e ds o m ei n c r e a s ei nr i s k ,t h eo p p o s i t eo f
what has been seen in some other studies [30,31]. How-
ever, the analyses were done on ever/never use of drug
with no distinction between drugs, dosage or duration,
and with no adjustment for actual lipid levels. Other
studies have seen a trend toward BMI as a risk factor
[32-34], where the current study saw a possible trend as
a protective factor. For antioxidants, the current study
also found (as in previous research) that there were no
consistent results related to nutrition and dietary
supplements.
As cataract type could not be reliably and consistently
discerned, the analyses were conducted for the presence
of any cataract. The vast majority of cataract type, when
indicated, were nuclear (> 96%). As prospective studies
can undertake analyses based on cataract type, this may
explain some of the differences found in the current
study.
The differences observed in gender are potentially due
to a combination of genetic factors and differences in
exposure or the clinical manifestations of diabetes, but
this retrospective analysis may also be confounded with
differences in healthcare utilization. Women, in general,
not only have recognized differences in potentially
important exposures but also visit healthcare providers
more frequently than do men, at least at younger ages
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Page 6 of 15[35]. In general, health risks due to smoking may decline
after cessation, perhaps returning to near baseline after a
number of years [36]. In addition, even though risks for
those who recently stopped smoking are likely similar to
those for current smokers, it is possible that early dis-
ease symptoms or clinical diagnoses may encourage
cessation.
Exposures were recorded as available in the EHR, and in
some cases (e.g., dietary intake) may reflect measures subse-
quent in time to cataract development. This is a recognized
limitation of the electronic analysis and would introduce
measurement error in analyses of risk to the degree that the
exposure as recorded did not provide a good estimate of
the subject’s exposure prior to developing cataract.
Table 2 Proportional hazards model for cataract-free survival stratified by birth cohort *
Factor Gender Group N Median #
Events
Main
Effect
p-
value
Interaction with
cohort p-value
Hazard
Ratio
< 1940
95%
Lower
95%
Upper
Hazard
Ratio
1960-77
95%
Lower
95%
Upper
Gender Female 9305 – 2167 –– – – – – – –
Male 7031 – 1437 < .001 0.007 0.85 0.79 0.92 0.50 0.36 0.70
Diabetes Female No 7999 – 1567 –– – – – – – –
Yes 1306 – 600 < .001 0.128 1.26 1.13 1.41 1.80 1.02 3.18
Male No 5788 – 910 –– – – – – – –
Yes 1243 – 527 < .001 0.060 1.36 1.20 1.54 2.34 1.05 5.22
Smoking
(ever)
Female No 5518 – 1355 –– – – – – – –
Yes 1427 – 170 0.029 0.079 1.31 1.03 1.67 0.74 0.48 1.16
Male No 3061 – 520 –– – – – – – –
Yes 1255 – 113 0.632 0.287 1.07 0.81 1.43 0.68 0.33 1.38
Steroid Use Female No 7751 – 1581 –– – – – – – –
Yes 1554 – 586 0.043 < 001 1.12 1.00 1.26 2.26 1.50 3.39
Male No 5919 – 991 –– – – – – – –
Yes 1112 – 446 0.590 0.017 1.04 0.91 1.18 2.32 1.04 5.16
Statin Use Female No 6616 – 1086 –– – – – – – –
Yes 2689 – 1081 < .001 0.952 1.27 1.15 1.41 1.37 0.82 2.31
Male No 4309 – 559 –– – – – – – –
Yes 2722 – 878 < .001 0.947 1.24 1.09 1.41 1.46 0.77 2.76
BMI Category Female Lowest 3100 23.0 754 –– – – – – – –
Middle 3103 28.0 720 0.887 – 0.95 0.84 1.07 0.81 0.54 1.21
Highest 3102 35.7 693 0.251 0.789 1.00 0.88 1.14 0.87 0.59 1.29
Male Lowest 2343 24.9 510 –– – – – – – –
Middle 2343 28.8 475 0.953 – 1.11 0.96 1.29 0.70 0.34 1.46
Highest 2345 33.9 452 0.409 0.235 1.06 0.92 1.24 1.02 0.53 1.97
HDL
Category
Female Lowest 1409 48.5 336 –– – – – – – –
Middle 1411 58.7 328 0.707 – 1.20 0.99 1.45 1.09 0.63 1.88
Highest 1410 70.4 293 0.965 0.795 1.02 0.83 1.25 1.24 0.72 2.13
Male Lowest 1166 37.7 290 –– – – – – – –
Middle 1169 46.2 240 0.145 – 0.98 0.80 1.21 0.65 0.25 1.69
Highest 1168 55.9 218 0.731 0.553 0.92 0.74 1.14 0.98 0.42 2.25
Antioxidant
Category
Female Lowest 1959 -0.8 481 –– – – – – – –
Middle 1962 -0.0 467 0.773 – 1.07 0.91 1.25 0.82 0.49 1.37
Highest 1961 0.7 474 0.149 0.465 1.01 0.86 1.18 0.98 0.59 1.61
Male Lowest 1305 -0.6 292 –– – – – – – –
Middle 1308 0.1 281 0.163 – 0.92 0.76 1.12 0.84 0.32 2.17
Highest 1307 0.8 291 0.309 0.434 0.96 0.79 1.16 0.55 0.18 1.64
* Models for factors other than gender and diabetes were fit in subjects without diabetes.
BMI = body mass index; HDL = high density lipoprotein
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Page 7 of 15Using EHR data has proven to be a viable tool for
research. Consistent with other studies, the well docu-
mented risk factors of age, gender, diabetes and steroid
use were found using an electronic algorithm to identify
t h ep r e s e n c eo fc a t a r a c tb ym ining diagnosis, medica-
tion, and lab data from the EHR. This indicates that the
EHR is a practical, cost effective, and an increasingly
available resource for doing research. However, there
a r ee l e m e n t st h a tn e e dt ob ec o n s i d e r e dw h e nu s i n g
data mined from EHRs.
While most research studies follow their cohort over
time, EHRs work with data available in clinical charts.
The EHR provides a wealth of information, but there
are also difficulties with doing research based on infor-
mation collected from clinical treatment. For many
subjects, information is available over a long period of
time; however, people can move into and out of the
clinical setting, resulting in minimal information or
gaps in information. There may also be problems with
data availability due to different departments going
Table 3 Logistic models for prevalence of age-related cataract *
Factor Gender Group N Median #
Events
Main
Effect
p-value
Interaction
with age
p-value
Odds
Ratio
Age 40
95%
Lower
95%
Upper
Odds
Ratio
Age 70
95%
Lower
95%
Upper
Gender Female 8401 – 1988 –– – – – – – –
Male 6028 – 1241 < .001 0.010 0.56 0.45 0.70 0.76 0.69 0.84
Diabetes Female No 7238 – 1470 –– – – – – – –
Yes 1163 – 518 0.036 0.272 1.92 1.31 2.83 1.55 1.33 1.81
Male No 4971 – 804 –– – – – – – –
Yes 1057 – 437 0.003 0.072 2.82 1.75 4.53 1.85 1.56 2.19
Smoking (ever) Female No 5002 – 1246 –– – – – – – –
Yes 1266 – 157 0.005 0.006 0.59 0.39 0.89 1.31 0.95 1.81
Male No 2650 – 469 –– – – – – – –
Yes 1039 – 91 0.014 0.032 0.40 0.20 0.76 0.95 0.64 1.40
Steroid Use Female No 7001 – 1475 –– – – – – – –
Yes 1400 – 513 < .001 0.002 2.44 1.75 3.42 1.38 1.15 1.66
Male No 5109 – 899 –– – – – – – –
Yes 919 – 342 0.014 0.040 2.35 1.31 4.22 1.31 1.05 1.64
Statin Use Female No 5903 – 995 –– – – – – – –
Yes 2498 – 993 0.261 0.494 1.39 0.94 2.05 1.21 1.04 1.41
Male No 3541 – 467 –– – – – – – –
Yes 2487 – 774 0.474 0.573 1.25 0.77 2.03 1.09 0.90 1.31
BMI Category Female Lowest 2407 22.71 461 –– – – – – – –
Middle 2418 27.36 571 0.670 0.563 0.92 0.66 1.27 0.88 0.73 1.06
Highest 2413 34.50 438 0.471 0.128 0.89 0.64 1.23 0.67 0.55 0.82
Male Lowest 1657 24.81 286 –– – – – – – –
Middle 1657 28.38 295 0.336 0.203 0.74 0.45 1.22 1.04 0.83 1.30
Highest 1657 32.99 223 0.844 0.702 0.68 0.41 1.14 0.74 0.58 0.93
Adjusted HDL Female Lowest 1234 49.19 351 –– – – – – – –
Middle 1235 59.30 224 0.593 0.637 1.14 0.72 1.81 0.93 0.72 1.21
Highest 1235 70.91 189 0.885 0.756 1.04 0.64 1.66 0.87 0.66 1.14
Male Lowest 965 38.46 273 –– – – – – – –
Middle 965 46.88 136 0.594 0.754 0.81 0.42 1.56 0.77 0.58 1.03
Highest 965 56.73 135 0.449 0.384 1.04 0.55 1.97 0.78 0.58 1.04
Antioxidant
Category
Female Lowest 1602 -0.79 374 –– – – – – – –
Middle 1603 -0.03 370 0.112 0.087 0.71 0.47 1.08 1.15 0.93 1.42
Highest 1603 0.66 327 0.936 0.956 0.82 0.55 1.23 1.06 0.85 1.32
Male Lowest 1009 -0.61 208 –– – – – – – –
Middle 1009 0.12 184 0.935 0.918 1.00 0.50 1.99 1.00 0.77 1.30
Highest 1009 0.80 171 0.857 0.825 0.96 0.48 1.92 1.03 0.79 1.36
* All models include age and interactions with age. Models for factors other than gender and diabetes were fit in subjects without diabetes.
BMI = body mass index; HDL = high density lipoprotein
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Page 8 of 15‘electronic’ at different times. In the Marshfield Clinic
system, the ophthalmology and dermatology depart-
ments were the last departments to be brought into
the electronic record system because of their heavy use
of drawings and diagrams. Also, there are limitations
on data historically that may vary by data type (i.e., lab
values were available over a longer period of time than
surgery data).
Specific to this study, eye care could have been
obtained at other facilities with referral into our system
for surgery, well after cataracts first developed. This
could delay the first diagnosis until the time surgery
was needed. Research data are gleaned from data
recorded by various providers in the system, which
does not allow for standardized collection, grading,
and documentation of the data. With the EHR, clinical
data are gathered in both coded and textual format
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Figure 6 Kaplan-Meier Estimates for Cataract Incidence by Smoking, Gender, and Birth Cohort with No Diabetes.
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Page 9 of 15and added to the EHR at the time of the patient visit.
The data are not restricted to a predefined data set or
a limited data collection period. Using EHR data can
be a cost effective way to determine phenotypes for
use in research. While broad phenotypes can be deter-
mined using EHR, it may be less useful in determining
specifics, in this case type of cataract. Missing specifi-
city would be an argument for encouraging more spe-
cific coding to make information more useful beyond
the scope of billing purposes. Developing a focus on
the ‘bigger picture’ would open up opportunities to use
collected data beyond a single intended purpose. One
problem noted was a bias that developed due to the
increase of frequency of eye exams for individuals
diagnosed with diabetes. Because of this, cataracts
were documented earlier in those with diabetes and at
a higher rate due to referral into the Marshfield Clinic
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Figure 8 Kaplan-Meier Estimates for Cataract Incidence by Steroid Use, Gender and Birth Cohort with No Diabetes.
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Page 10 of 15system and/or their more regularly scheduled ophthal-
mic exams.
Strengths
Strengths of this study include being population-based
with a large sample size from a stable cohort with medi-
cal records available over a long period of time. Using
the EHR also allows for being able to continually add
information so that data are not restricted to a limited
collection period. Another strength is that age at diag-
nosis was able to be reliably ascertained, a common
shortcoming in other studies.
Limitations
Data were not collected under a standardized protocol,
but instead were based on clinical care as recorded in
the EHR. With data collected in this manner, there are
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Figure 10 Kaplan-Meier Estimates for Cataract Incidence by Statin Use, Gender, and Birth Cohort with No Diabetes.
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Page 11 of 15variations over time (it was not uncommon for severity
of cataract to ‘bounce’ around even with the same provi-
der) and between treatment providers (different treat-
ment providers may give different severity, even when
seen at the same time or within in a small timeframe
[referral/consultation]) in the subjective ratings of catar-
act severity. No distinction was made between severity
of cataract or type of cataract made by opticians, opto-
metrists, and ophthalmologists. Some subjects have lim-
ited data available as they may move in and out of the
system, seek some of their care at other facilities, or
come in as referrals for surgery. While not being able to
determine cataract type was not a major limitation in
determining the usefulness of EHR data in research, the
ideal would be to have type identified. Different types of
cataracts can have different risk factors, so working
towards better understanding of cataract development
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Figure 12 Kaplan-Meier Estimates for Cataract Incidence by BMI (lower vs. upper third), Gender, and Birth Cohort with No Diabetes.
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Page 12 of 15and prevention would be enhanced by being able to
determine cataract type.
Conclusion
Using coded EHR data is a viable and efficient means to
identify subjects with cataract for research, but the data
for most subjects were not specific enough at our insti-
tution to identify type. The next steps will be to develop
electronic algorithms and tools to better identify catar-
act type. It will be important to see how well these algo-
rithms transfer to other EHR systems. Another future
step will be to move towards modeling that would
include genetic and other environmental factors.
List of abbreviations
BMI: body mass index; CPT: Current Procedural Terminology; DHQ: Dietary
History Questionnaire; EDPRG: Eye Diseases Prevalence Research Group; EHR:
electronic health record; eMERGE: electronic MEdical Records and Genomics;
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9th revision; ICR: Intelligent Character Recognition; NLP: Natural Language
Processing; PMRP: Personalized Medicine Research Project.
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